What is the maximum recommended daily dose of trelagliptin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Trelagliptin Maximum Dose Per Day

The maximum recommended daily dose of trelagliptin is 100 mg once weekly (not daily), as this is a once-weekly DPP-4 inhibitor, not a daily medication. 1, 2, 3, 4, 5

Standard Dosing

  • Standard dose: Trelagliptin 100 mg administered orally once per week for patients with normal renal function 1, 3, 4, 5
  • Administration: Can be taken at any time of day, with or without food 4, 5
  • Monotherapy or combination: The 100 mg weekly dose applies whether used as monotherapy or in combination with other antidiabetic agents including metformin, sulfonylureas, glinides, α-glucosidase inhibitors, biguanides, thiazolidinediones, or insulin 3, 4

Dose Adjustments in Renal Impairment

Severe renal impairment or end-stage renal disease:

  • Reduced dose: 25 mg once weekly for patients with creatinine clearance <30 mL/min or those on hemodialysis 2
  • This represents a 75% dose reduction from the standard 100 mg weekly dose 2
  • The 25 mg weekly dose demonstrated significant HbA1c reduction of -0.71% compared to placebo in patients with severe renal impairment or end-stage renal disease 2

Moderate renal impairment:

  • Modeling studies suggest dose reduction by half (50 mg weekly) may be appropriate in patients with severe renal impairment, though clinical recommendations support the 25 mg weekly dose 6

Important Clarification

The FDA drug label references 7 in the evidence provided are incorrect and refer to triprolidine (an antihistamine), not trelagliptin. This appears to be a database error. The correct dosing information comes from the clinical trial data 1, 2, 3, 4, 5.

Safety Profile

  • Well-tolerated: Treatment-emergent adverse events were comparable to placebo and other DPP-4 inhibitors, with most being mild-to-moderate 2, 4, 5, 8
  • Hypoglycemia risk: No severe hypoglycemia was reported when trelagliptin was used with insulin, making it a safer option than sulfonylureas 3
  • Long-term safety: 52-week studies demonstrated sustained safety across all combination therapies 4

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.